Mithra Pharmaceuticals S.A.

MITRA

BE0974283153

Pharmaceuticals

Real-time Euronext Bruxelles Other stock markets 03:15:41 2024-04-16 am EDT			5-day change	1st Jan Change
0.22 ^EUR	-4.35%		-1.35%	-82.46%

Mar. 08	Mithra Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 05	Mithra Pharmaceuticals to Initiate Monetization Process Involving Sale of Assets, Business	MT

Mithra Pharmaceuticals S A : Announces 2022 Half Year Results

September 23, 2022 at 01:40 am EDT

Liege, Belgium, 23 September 2022 - 7:30 CEST - Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces its financial results for the six-month period ending on 30 June 2022, prepared in accordance with IFRS. The full interim report is available on the Investors section of the website.

Read the press release

Attachments

Original Link
Original Document
Permalink

Disclaimer

Mithra Pharmaceuticals SA published this content on 23 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 September 2022 05:39:09 UTC.

Latest news about Mithra Pharmaceuticals S.A.

Mithra Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08	CI
Mithra Pharmaceuticals to Initiate Monetization Process Involving Sale of Assets, Business	Mar. 05	MT
Mithra Pharmaceuticals Terminates CEO; Names CFO, COO as Successors	Mar. 05	MT
Mithra Pharmaceuticals SA Announces CEO Changes	Mar. 05	CI
Mithra Pharmaceuticals Exits Stake in Mayne Pharma	Feb. 16	MT
An undisclosed buyer acquired a 5.06% stake in Mayne Pharma Group Limited from Mithra Pharmaceuticals SA for AUD 21 million	Feb. 14	CI
Mithra: share price falls, financial visibility reduced	Feb. 06	CF
Mithra : Goldman Sachs reduces its stake to below 3%.	Dec. 27	CF
Mithra Pharmaceuticals Completes Pediatric Study of Contraceptive Product in Adolescent Women	Dec. 21	MT
Mithra Signs Agreement with Gedeon Richter for Commercialization of Estelle, Donesta in China	Dec. 04	MT
Mithra Pharmaceuticals SA and Gedeon Richter Plc. Signs Binding Head of Terms to Commercialize Estelle and Donesta in China	Dec. 04	CI
Mithra Pharmaceuticals to Conduct Additional Data Analysis for Menopause-candidate Drug	Nov. 30	MT
Certain Ordinary Shares of Mithra Pharmaceuticals SA are subject to a Lock-Up Agreement Ending on 26-NOV-2023.	Nov. 25	CI
Mithra Pharmaceuticals Obtains US Patent for Contraceptive Pill	Nov. 07	MT
Mayne Pharma Gets Additional US Patent for Contraceptive	Nov. 06	MT
Mithra and Searchlight Pharma Sign DONESTA Licensing Agreement for Canada	23-10-26	CI
Mithra Pharmaceuticals Signs License Agreement for Menopause Drug With Canada's Searchlight Pharma	23-10-26	MT
Mithra and Searchlight Pharma Inc. Signs License and Supply Agreement for the Canadian Rights to DONESTA	23-10-26	CI
Mithra Pharmaceuticals' License Partner Files for Estelle's Marketing Approval in Japan; Shares Jump	23-10-23	MT
Mithra Announces Presentation of Positive Data on Estetrol (E4) Native Estrogen at NAMS 2023	23-09-27	CI
Mithra Pharmaceuticals SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
Mithra Pharmaceuticals SA(ENXTBR:MITRA) dropped from S&P Global BMI Index	23-09-18	CI
Mithra Pharmaceuticals Raises EUR20 Million in Private Placement	23-08-29	MT
Mithra Pharmaceuticals SA announced that it has received ?20 million in funding from Armistice Capital, LLC	23-08-27	CI
Mithra Pharmaceuticals to Raise EUR20 Million in Private Placement	23-08-24	MT

Chart Mithra Pharmaceuticals S.A.

Duration

Period

More charts

Company Profile

Mithra Pharmaceuticals S.A. is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra Pharmaceuticals S.A. explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle®, the Company is now focusing on its second product Donesta®, the next-generation hormone therapy. Mithra Pharmaceuticals S.A. also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO.

Sector

Pharmaceuticals

Calendar

2024-05-15 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Mithra Pharmaceuticals S.A.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

0.23 EUR

Average target price

0.11 EUR

Spread / Average Target

-52.17%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
MITHRA PHARMACEUTICALS S.A.	-82.46%	16.9M
CSL LIMITED	-4.17%	86.99B
SAMSUNG BIOLOGICS CO.,LTD.	+4.34%	40.68B
BIOGEN INC.	-23.95%	28.61B
UCB	+50.51%	24.1B
BIOMARIN PHARMACEUTICAL INC.	-5.09%	17.37B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-32.11%	13.72B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-5.10%	12.49B
INCYTE CORPORATION	-14.91%	12B
SWEDISH ORPHAN BIOVITRUM AB	-5.54%	7.94B

Biopharmaceuticals